← Back to headlines
J&J Stock Upgraded by Analysts Citing New Drugs
Leerink analysts upgraded Johnson & Johnson shares from hold to a buy equivalent, citing the company's promising slate of new drugs. This positive assessment comes in an AI-obsessed market, highlighting the value of traditional healthcare innovation.
13 May, 17:26 — 13 May, 17:26
Sources
Showing 1 of 1 sources
Related Stories
Anthropic Agrees to $45 Billion AI Computing Deal With Nscale
28m ago
Canada Prepares Counter-Tariffs as US Trade Negotiations Fail
37m ago
Meta Agrees to $18 Billion Settlement With U.S. States Over Teen Social Media Safety
37m ago
Investors Eye Nvidia’s Upcoming Earnings Amid Strong AI Chip Demand Forecasts
40m ago